BioNexus Gene Lab Corp
corporate_fare Company Profile
BioNexus Gene Lab Corp (NASDAQ:BGLC) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 10 items for BGLC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for BGLC spans 10-Q, 8-K, SCHEDULE 13D, 10-K.
Recent high-impact activity:
- BioNexus Q3: Revenue Down 97.9%, Going Concern Doubt Reiterated, 560K Shares Issued for RYET Deal
- BioNexus Grants Exclusive CogniAI Healthcare Licence and Issues 16% of Shares to RYET
- CEO Su-Leng Tan Lee Receives 338,709 Fully Vested Shares, Boosting Stake to 11.5%
- BioNexus Issues $800K in Stock Awards, Reappoints CEO, and Reiterates Going Concern Doubt
- BioNexus Gene Lab Corp's Q1 Revenue Crashes 99% to $22.84K, Deepening Going Concern Worries
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 3,180 shares in BGLC as of the October 30, 2026 settlement, a 64.9% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 10.7% of BGLC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.